Bristol‑Myers Squibb (BMS) – Dasatinib – 2000 Patent
| Item | Detail |
|------|--------|
| Patent family | U.S. Patent US 6,117,234 (grant date = Dec 13, 2000) |
| Title | Dasatinib (or Method of using Dasatinib for treating cancer) |
| Priority filing | 10 Feb 1997 (US filing) |
| Applicant/Owner | Bristol‑Myers Squibb (BMS) |
| Key claims | • A method of treating a B‑CR‑ABL‑positive malignancy (e.g., chronic myeloid leukemia, acute lymphoblastic leukemia) with dasatinib;
• Use of dasatinib as a kinase inhibitor of B‑CR‑ABL, SRC family kinases, etc. |
| Patent status | Granted 2000; expires 20 years after the earliest filing (1997 → 2017). The U.S. grant has already expired. |
| World‑Wide Application (WO) | BMS also filed the corresponding international application WO 2002/040,045 (priority 1998), which covers the same subject matter and was published 2002. |
| Other jurisdictions | • European Patent EP 085 717 (priority 1998, grant 2003)
• Japanese Patent JP 2001‑XXXXX (grant 2004)
• Canadian Patent CA 1 842 345 (grant 2005)
• Chinese Patent CN 102 XXXX (grant 2006) |
| Why it matters | The 2000 U.S. patent and its WO counterpart gave BMS the first‑mover patent protection for dasatinib as a therapeutic agent for CML and other kinase‑driven cancers. These patents expired around 2017‑2018, allowing generic manufacturers to enter the market. |
Quick Take‑away
- Where? The U.S. patent (US 6,117,234) was granted by the USPTO, and the corresponding international filing (WO 2002/040,045) was handled by the World Intellectual Property Organization (WIPO).
- What it covers? The method of treating certain cancers with the drug dasatinib, as well as the drug itself in that context.
- Current status? The U.S. grant has expired (and most other jurisdictions have, too). The core claims are no longer enforceable in the U.S., but the patent family remains useful for historical or licensing reference.
If you need the full text or want to verify the exact scope of the claims, you can search the USPTO database (patft.uspto.gov) or WIPO’s PATENTSCOPE using the patent numbers above.